Cagrilintide

most data

Also seen as: cagri, AM833, NNC0174-0833

The Dose Guy’s verdict

Aug 28, 2026
3 sources

The hunger killer, but not a solo act. Cagrilintide hits the amylin pathway, a different hunger circuit than the incretins, and the community’s main use for it is restoring appetite suppression when a GLP-1 agonist fades. Solo, the data is thinner than the big three. Stacked with semaglutide, the combination raises the ceiling past what either does alone. Think of it as the reload, not the replacement.

Would I take it?Yes, as the stack piece.

What it is

Cagrilintide is a long-acting amylin analog. Amylin is the hormone your pancreas releases alongside insulin after a meal: it slows gastric emptying, tells the brain the meal is done, and disappears within minutes. Cagrilintide turns that brief post-meal signal into sustained appetite control. It works through different receptors than the GLP-1 agonists, which is why stacking them covers more of the hunger map than either alone.

The combination of cagrilintide and semaglutide, called CagriSema, is what Novo Nordisk is pushing through phase 3. For the community, though, the more common play is adding cagrilintide at a small dose alongside whatever incretin you’re already running, whether that is retatrutide, tirzepatide, or semaglutide.

What the research shows

Solo, the evidence is mid-depth. Stacked with semaglutide, the numbers jump:

Solo cagrilintide at 26 weeks: weight loss of 6.0% to 10.8% across doses of 0.3 to 4.5 mg weekly, versus 3.0% with placebo.Lancet 2021 · phase 2 · n=706

The stack proof of concept: cagrilintide 2.4 mg added to semaglutide 2.4 mg produced 17.1% weight loss at 20 weeks, versus 9.8% on semaglutide alone.Lancet 2021 · phase 1b · n=95

REDEFINE 1 at 68 weeks: CagriSema, 2.4 mg of each component, produced 20.4% weight loss versus 3.0% with placebo.NEJM 2025 · phase 3a · n=3417

Realistic protocols

The standard play is stacking it. You add cagrilintide to whatever incretin you’re already running at a small weekly dose. The amylin signal covers hunger circuits the GLP-1 pathway does not reach, so the combination restores appetite suppression that may have faded over months on an incretin alone. Start at the bottom and see how your hunger responds.

Pin it subcutaneously once a week. The community runs it on the same day as their incretin, though splitting days works too. Same alcohol caution as the rest of the class: the slowed gut makes drinking rougher, especially with two appetite signals stacked.

Stack start0.25–0.5 mg/wkSub-q, alongside your incretin. Start low.

Stack hold0.5–1 mg/wkWhere most people settle. If hunger is handled, stay.

Raise+0.25–0.5 mgOnly if appetite creeps back. Give each change a few weeks.

Solo ceiling4.5 mg/wkTrial max for solo use. Most people stack instead.

Side effects

The amylin pathway brings its own GI load, and stacking doubles down:

commonNausea, especially early and at higher doses. The amylin signal hits the gut hard, and stacking with an incretin compounds it.

anecdotalInjection site reactions reported in the community. Rotate sites.

monitorWhen stacked with an incretin and insulin, watch for low blood sugar. The combination slows glucose absorption from multiple angles.

monitorSolo cagrilintide carried a higher serious adverse event rate than semaglutide in a meta-analysis. Another reason the stack, not solo use, is the play.

unknownLong-term safety data is limited. The REDEFINE trials are the longest controlled runs.